Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12693160 | 0.89 | ELOVL6 (0.43) | PIK3CANAMPTKCNH2 | |
| SCHEMBL12693189 | 0.89 | PIK3CA (0.41) | PIK3CAVNN1MCHR1HTR1AADRA2A | |
| SCHEMBL12693067 | 0.88 | EPHX2 (0.47) | KCNH2GABRA5 | |
| SCHEMBL12693025 | 0.88 | NAMPT (0.45) | MCHR1NAMPTKCNH2 | |
| SCHEMBL12541988 | 0.84 | TAS1R3 (0.43) | PIK3CAVNN1NAMPTKCNH2 | |
| SCHEMBL12543681 | 0.84 | SCN9A (0.44) | PPARDCCR6 | |
| SCHEMBL12543679 | 0.84 | SCN9A (0.44) | PPARDCCR6 | |
| SCHEMBL12543554 | 0.84 | KCNH2 (0.43) | PIK3CAKCNH2 | |
| SCHEMBL12541985 | 0.84 | TAS1R3 (0.43) | PIK3CAVNN1NAMPTKCNH2 | |
| SCHEMBL12543553 | 0.84 | KCNH2 (0.43) | PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | PIK3CA 4467/4885VNN1 4006/4885MCHR1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.